ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,142.15
-0.06%
Dow Jones
38,778.10
0.49%
Gold vs US Dollar
2,319.455
-0.58%
Brent Oil
83.96
2.23%
Bitcoin
66,390.38
-0.37%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Senti Biosciences Inc (SNTI) Share Price

SNTI Senti Biosciences Inc

0.2372
-0.0092 (-3.73%)
After Hours
Last Updated: 21:30:00
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Senti Biosciences Inc NASDAQ:SNTI NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.0092 -3.73 0.2372 0.232 0.2699 0.2499 0.2303 0.24 85,455 20:30:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 2.56M -71.06M -1.5952 -0.15 10.69M
 Type  Size  Price  Time  Units 
 9 29 0.2372 20:45:34 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore SNTI News
29/05/202421:14EDGAR2Form ARS - Annual Report to Security Holders
29/05/202421:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
29/05/202421:07EDGAR2Form DEF 14A - Other definitive proxy statements
17/05/202422:19EDGAR2Form PRE 14A - Other preliminary proxy statements
17/05/202422:17EDGAR2Form 8-K - Current report
13/05/202413:15GLOBESenti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
09/05/202421:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Period
Draw mode
Data Downloads for SNTI

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Senti Biosciences Inc Articles